**Overview**
Pexidartinib is a tyrosine kinase inhibitor with selective and strong inhibitory activity against the colony-stimulating factor 1 receptor (CSF1R); pexidartinib also inhibits KIT and FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (Tap 2019). Overexpression of the CSF1R ligand promotes cell proliferation and accumulation in the synovium. Pexidartinib inhibits proliferation of a CSF1R dependent cell line.

**Coverage Guidelines**
Authorization may be granted for members who are currently receiving treatment and stable with Turalio, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs. OR
Authorization may be granted for members when all the following criteria are met, and documentation is provided:
1. The member is ≥ 18 years of age
2. The member has a diagnosis of tenosynovial giant cell tumor
3. The provider specialty is Oncology or medication is being prescribed in consultation with an oncologist
4. The member is not a candidate for surgery

**Continuation of Therapy**
Reauthorization requires physician documentation of improvement of member’s condition.

**Limitations**
Authorizations will be approved for 12 months.
References

Review History
01/23/2020 – Reviewed and Approved P&T Mtg (effective 6/1/20)

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.